Clinical trials: CGM
Stress Urinary Incontinence (SUI)
Stress Urinary Incontinence for Female Patients (CGM MUIT-2301)
This study is a multicenter, prospective, randomized, double-blind, sham-controlled clinical trial conducted in female patients with stress urinary incontinence.
- Trial name
- NCT07440927
- Testing
- Ceragem Innerfit medi-tech
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Ceragem Clinical Inc.
Type II Diabetes Mellitus
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.
- Trial name
- NCT01262586
- Testing
- Vildagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes Mellitus
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary Objective: To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
- Trial name
- inRange (NCT04075513)
- Testing
- Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Diabetes Mellitus
Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System
This is a prospective, non-randomized, observational study conducted in the United States.Up to sixty (60) subjects will be enrolled.
- Trial name
- GLYCOAIM (NCT01627210)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- DexCom, Inc.
Diabetes
Performance of the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus
The purpose of this prospective observational study is to establish the performance and safety of the Dexcom G6 CGM System utilized for up to a 10-day wear period in pregnant women with diabetes mellitus.
- Trial name
- NCT03935191
- Testing
- Dexcom CGM System
- Volunteers
- 60 people
- Sponsor
- DexCom, Inc.
Weight Loss, Metabolic Syndrome
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence…
- Conditions
- Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity
- Trial name
- NCT05121844
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 31,187 people, healthy volunteers welcome
- Sponsor
- Signos Inc
T1DM - Type 1 Diabetes Mellitus
The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus
The purpose of the investigation is to evaluate the performance of the I3 CGM in Pediatric Patients with Type 1 Diabetes Mellitus (T1DM) according to the FDA's special controls for iCGM.
- Trial name
- NCT05908448
- Testing
- 13 CGM (continuous glucose monitor)
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Sinocare
Diabetes
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
- Trial name
- NCT06483945
- Testing
- Dexcom CGM G6/G6 Pro/G7
- Where
- 2 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- DexCom, Inc.
Diabetes Mellitus
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.
This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin…
- Trial name
- GRANT (NCT06999551)
- Testing
- switch NPH to glargin
- Where
- Tunisia
- Volunteers
- 60 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1D) or insulin-dependent Type 2 diabetes (T2D) on a multiple daily injection (MDI) regime.
- Trial name
- NCT06704672
- Testing
- Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
- Where
- 20 sites in Poland, Turkey (Türkiye)
- Volunteers
- 270 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Type 2 Diabetes
Feasibility Trial of the Bios Device for Continuous Glucose Monitoring
The study is an open-label, prospective, within-subject comparison of the Bios device readings versus venous blood sample glucose readings, glucose readings from a Dexcom CGM and an SMBG device in subjects previously diagnosed…
- Trial name
- NCT04226846
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- GraphWear Technologies Inc.
Diabetes Mellitus
A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus
This study will be conducted in France and will evaluate the usefulness of using a long-term subcutaneously inserted continuous glucose monitoring (CGM) sensor (the Eversense XL CGM System) to improve glycemic control in patients…
- Trial name
- NCT03445065
- Testing
- Eversense XL CGM System, Usual SMBG or FGM device used by participants
- Where
- 20 sites in France
- Volunteers
- 239 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
This multi-center study is a 26-week randomized controlled trial (RCT) in which adults (≥18 years) with type 2 diabetes (T2D) not using insulin and managed in a primary-care setting will be randomly assigned 1:1 to either use of…
- Trial name
- NCT06601166
- Testing
- CGM
- Where
- 21 sites in United States
- Volunteers
- 283 people
- Sponsor
- DexCom, Inc.
Diabetes Mellitus
Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial
The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.
- Trial name
- NCT05806554
- Testing
- Continuous glucose monitoring device
- Where
- 6 sites in United States, Germany
- Volunteers
- 159 people
- Sponsor
- Sinocare
Continuous Glucose Monitoring
Cascade Continuous Glucose Monitor (CGM) 15-Day US Performance Assessment
To assess a 15-day wear period of the Cascade Continuous Glucose Monitoring (CGM) System
- Trial name
- CUSP (NCT04397965)
- Testing
- Cascade Continuous Glucose Monitor
- Volunteers
- 10 people
- Sponsor
- WaveForm Technologies Inc.
Diabetes Mellitus
Effect of CGM on Glucose Control in Non-insulin-treated Patients With Type 2 Diabetes Mellitus
The clinical value of CGM for diabetic patients undergoing insulin therapy has been widely recognized, but the evidence-based support for its use in non-insulin-treated type 2 diabetic patients remains insufficient.
- Trial name
- CONVERT (NCT06587438)
- Testing
- Sinocare iCan I3 CGM, Sinocare jinzhi+Blood glucose meter
- Where
- 6 sites in China
- Volunteers
- 160 people
- Sponsor
- Sinocare